62 related articles for article (PubMed ID: 36764998)
21. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
22. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.
Xu N; Hua Z; Ba G; Zhang S; Liu Z; Thiele CJ; Li Z
J Exp Clin Cancer Res; 2019 Mar; 38(1):118. PubMed ID: 30850026
[TBL] [Abstract][Full Text] [Related]
23. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
24. Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.
Dehner CA; Armstrong AE; Yohe M; Shern JF; Hirbe AC
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680895
[TBL] [Abstract][Full Text] [Related]
25. Reversing oncogenic transformation with iron chelation.
Abdelaal G; Veuger S
Oncotarget; 2021 Jan; 12(2):106-124. PubMed ID: 33520115
[TBL] [Abstract][Full Text] [Related]
26. Iron and Cancer: 2020 Vision.
Torti SV; Torti FM
Cancer Res; 2020 Dec; 80(24):5435-5448. PubMed ID: 32928919
[TBL] [Abstract][Full Text] [Related]
27. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A
Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630642
[TBL] [Abstract][Full Text] [Related]
29. Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production.
Fiorillo M; Tóth F; Brindisi M; Sotgia F; Lisanti MP
Cells; 2020 Jun; 9(6):. PubMed ID: 32585919
[TBL] [Abstract][Full Text] [Related]
30. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.
Brown RAM; Richardson KL; Kabir TD; Trinder D; Ganss R; Leedman PJ
Front Oncol; 2020; 10():476. PubMed ID: 32328462
[TBL] [Abstract][Full Text] [Related]
31. Signaling pathways in Rhabdomyosarcoma invasion and metastasis.
Ramadan F; Fahs A; Ghayad SE; Saab R
Cancer Metastasis Rev; 2020 Mar; 39(1):287-301. PubMed ID: 31989508
[TBL] [Abstract][Full Text] [Related]
32. Targeting ferroptosis in rhabdomyosarcoma cells.
Dächert J; Ehrenfeld V; Habermann K; Dolgikh N; Fulda S
Int J Cancer; 2020 Jan; 146(2):510-520. PubMed ID: 31173656
[TBL] [Abstract][Full Text] [Related]
33. Rhabdomyosarcoma.
Skapek SX; Ferrari A; Gupta AA; Lupo PJ; Butler E; Shipley J; Barr FG; Hawkins DS
Nat Rev Dis Primers; 2019 Jan; 5(1):1. PubMed ID: 30617281
[TBL] [Abstract][Full Text] [Related]
34. Sucrosomial
Asperti M; Gryzik M; Brilli E; Castagna A; Corbella M; Gottardo R; Girelli D; Tarantino G; Arosio P; Poli M
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30241424
[TBL] [Abstract][Full Text] [Related]
35. Iron and Cancer.
Torti SV; Manz DH; Paul BT; Blanchette-Farra N; Torti FM
Annu Rev Nutr; 2018 Aug; 38():97-125. PubMed ID: 30130469
[TBL] [Abstract][Full Text] [Related]
36. Cell growth potential drives ferroptosis susceptibility in rhabdomyosarcoma and myoblast cell lines.
Codenotti S; Poli M; Asperti M; Zizioli D; Marampon F; Fanzani A
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1717-1730. PubMed ID: 29971532
[TBL] [Abstract][Full Text] [Related]
37. Molecular diagnostics in the management of rhabdomyosarcoma.
Arnold MA; Barr FG
Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850
[TBL] [Abstract][Full Text] [Related]
38. Rhabdomyosarcoma.
Dasgupta R; Fuchs J; Rodeberg D
Semin Pediatr Surg; 2016 Oct; 25(5):276-283. PubMed ID: 27955730
[TBL] [Abstract][Full Text] [Related]
39. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.
Bordini J; Galvan S; Ponzoni M; Bertilaccio MT; Chesi M; Bergsagel PL; Camaschella C; Campanella A
Leukemia; 2017 Apr; 31(4):967-970. PubMed ID: 27881873
[No Abstract] [Full Text] [Related]
40. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.
Zanganeh S; Hutter G; Spitler R; Lenkov O; Mahmoudi M; Shaw A; Pajarinen JS; Nejadnik H; Goodman S; Moseley M; Coussens LM; Daldrup-Link HE
Nat Nanotechnol; 2016 Nov; 11(11):986-994. PubMed ID: 27668795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
